nanotech investing Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
nanotech investing Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
nanotech investing Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
nanotech investing Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
nanotech investing Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
nanotech investing Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
NevGold Appoints Dale Found as CFO, Current CFO Bob McKnight Transitions to VP Engineering Studies To Support Next Project Development Phase
Skyharbour Files Independent NI 43-101 Technical Reports on its Co-Flagship Moore and Russell Lake Uranium Projects, Saskatchewan
Red Metal Resources Reports First Ore Delivery from Farellon Ahead of Schedule, Launching Non-Dilutive Royalty Revenue
